

4.0.03 DOC Cmte minutes

Document not locked to allow for amendments

Lung cancer Committee meeting

Date: 18/06/2018 & 19/06/18

Location: NICE offices London

Minutes: Final



Committee members present:	
Gary McVeigh (GM) (Chair)	Present for all
Shahzeena Aslam (SA)	Present for all
Elaine Borg (EB)	Present for all
Lynn Campbell (LC)	Present for all
Sujal Desai (SD)	Present for all
Jesme Fox (JF)	Present for all
Tom Haswell (TH)	Present for all
Andrea McIver (AM)	Present for all
Sue Maughn (SM)	Present for all
Neal Navani (NN)	Present for all
Steve Connor (SC)	Day 2 from item 6
Rhiannon Walters-Davies (RW)	Present for day 1
Douglas West (DW)	Present from item partway through item 2, day 1 Present for all day 2
Nigel Westwood	Present from item partway through item 2, day 1 Present for all day 2
Clifford Wyn Jones (CW)	Present from item partway through item 2, day 1 Present for all day 2

In attendance:		
Sohaib Ashraf (SAS)	NICE – Technical Analyst Health Economics	Present for all day 1 Present from partway

4.0.03 DOC Cmte minutes

		through item 2, day 2
James Hall (JH)	NICE – Editor	Present for all
Ross Maconachie (RM)	NICE – Technical Advisor Health Economics	Present for all day 1 Present from partway through item 2, day 2
Toby Mercer (TM)	NICE – Technical Analyst	Present for all
Caroline Mulvihill (CM)	NICE – Technical Advisor	Present for all
Vonda Murray (VM)	NICE – Project Manager	Present for all

Observers:	
Rui Martins	NICE - Technical Analyst Health Economics – present for day 1, until item 4
Shreya Shukla	NICE - Technical analyst – present for day 1, until item 4
Jeffrey Tabiri-Essuman	NICE - Technical analyst – present for day 1, until item 4

Apologies:	
Steve Connor	Committee member – day 1
Rupert Franklin	NICE – Commissioning Manager - day 1 & 2
Sue Spiers	NICE – Associate Director Guideline Updates Team day 1 & 2
Rhiannon Walters-Davies	Committee member – day 2

Day 1 – Monday 18th June 2018

<p>Item 1</p> <ul style="list-style-type: none"> • Welcome • Objectives • Declarations of interest • Minutes of the last meeting
<p>Item 1</p> <p>The Chair welcomed the Committee members, and attendees to day 1, of the 7th committee meeting on lung cancer.</p> <p>The objectives of the meeting, were outlined by the Chair, for day 1 of the meeting. The minutes were reviewed from Gcomm 6; Wednesday 16th May 2018. The minutes were agreed to be an accurate record.</p> <p>The DOI register was made available to the Chair, and committee. The Chair reviewed the DOI register, a number of new declarations were made, and these are</p>

4.0.03 DOC Cmte minutes

noted below. The DOI's were considered by the Chair. It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

Attendee	Declaration	Action
Shahzeena Aslam	Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.	Direct financial. Declare and participate. Not specific to any topic covered in the scope of the guideline
Shahzeena Aslam	Paid work for IQVIA clinical research organisation. Involves analysis of anonymous data that has been collected from patients including lung cancer patients with an emphasis on recurrence, toxicity and death. Data collected will be "real world" data from patients not enrolled in clinical trials but undergoing pharmacological treatment with licensed drugs.	Direct financial. Declare and participate The work is provision of generic real world data with no direct link to the scope of the guideline.
Lynn Campbell	Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.	Direct financial (non-specific) (travel and subsistence only) Declare and participate Not specific to any topic covered in the scope of the guideline
Sujal Desai	Run an educational course for Boehringer Ingelheim, on interstitial lung diseases. Honorarium and travel costs will be paid	Direct financial (non-specific). Declare and participate Not specific to any topic covered in the scope of the guideline
Jesme Fox	31st May, attended a Global Oncology Advocacy Leaders Meeting in Chicago. Travel and accommodation expenses paid by Bristol-Myers Squibb. The topics	Direct financial (travel and subsistence), (non-specific)

4.0.03 DOC Cmte minutes

	discussed general cancer issues, not relevant to lung cancer guideline.	Declare and participate Not specific to any topic covered in the scope of the guideline
Rhiannon Walter-Davies	Attend an advisory board, for Astra Zeneca, 5th July 2018, on Durvalumab. Accommodation, travel and expenses paid. Honorarium paid to education fund. The topics discussed, were not relevant to lung cancer guideline.	In direct financial (non-specific) Declare and participate Not specific to any topic covered in the scope of the guideline
Rhiannon Walter-Davies	Attend an internal meeting (educational) for Boehringer, 26th June 2018, on Afatanib. Honorarium paid to education fund. Accommodation, travel and expenses paid.	In direct financial Declare and participate
Rhiannon Walter-Davies	Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.	Direct financial (travel and subsistence) Declare and participate. Not specific to any topic covered in the scope of the guideline
Item 2 Lay members slot		
Item 2 Lay members given the opportunity to ask questions of NICE staff relating to the review questions.		
Item 3 Algorithm feedback from targeted consultation		
Item 3 CM presented the comments received from the targeted consultation exercise. The committee discussed the comments, and agreed changes to the algorithm as required.		
Item 4 3.1 What is the clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage NSCLC? <ul style="list-style-type: none"> • Presentation of network meta-analyses • Discuss economic model 		

4.0.03 DOC Cmte minutes

Item 4

RM presented the network meta-analyses, on clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage non-small cell lung cancer. The committee discussed the evidence presented. RM also presented the finalised economic model structure and the underpinning data. The committee discussed these.

Item 5

3.1 What is the clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage NSCLC?

- Discuss health economic model results
- Agree recommendations

Item 5

RM presented the results of the health economic model. The committee discussed the evidence presented, and reviewed and updated recommendations accordingly.

Item 6

3.2 What is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0)?

- Evidence review
- Health economics
- Agree recommendations

Item 6

TM presented the evidence found on, what is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0).

Item 7

3.2 What is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0)?

- Agree recommendations

Item 7

TM presented additional evidence for this review question. The committee discussed the evidence presented, and reviewed and updated recommendations accordingly.

Item 8

4.1 What is the clinical and cost effectiveness of cranial irradiation for brain metastases in people with NSCLC?

- Brain tumours (primary) and brain metastases in adults recommendations discussion

Item 8

Brought forward from day 2, item 5. CM presented the recommendation made by the

4.0.03 DOC Cmte minutes

Brain Tumour and Brain Metastases Guideline Committee. The committee discussed this and agreed recommendations.

Item 9

AOB

Item 9

No other business to discuss

Item 10

Summary and next steps

Item 10

The Chair thanked the committee for their contribution, and the committee agreed a revised start time for day 2 of GComm7.

Day 2 – Tuesday 19th June 2018

Item 1

- Welcome
- Objectives
- Declarations of interest

Item 1

The Chair welcomed the Committee members, and attendees to day 2, of the 7th committee meeting on lung cancer.

The DOI register was made available to the Chair, and committee. The DOI's were considered by the Chair. It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

Apologies were noted, as recorded above. The objectives of the meeting, were outlined by the Chair, for day 2 of the meeting.

Item 2

Lay members slot

Item 2

Lay members given the opportunity to ask questions of NICE staff relating to the review questions.

Item 3

- Recommendation refresh
 - Impact review of recommendations
 - Staging

Item 3

4.0.03 DOC Cmte minutes

CM went through the recommendations, the committee reviewed the recommendations, considering how they impacted upon each other and whether any terminology was outdated. Recommendations were updated accordingly.

Item 4

- Edited recommendations

Item 4

CM went through the recommendations that have been made to date, providing feedback from the Editor on the recommendations. The committee reviewed and updated recommendations accordingly.

Item 5

4.1 What is the clinical and cost effectiveness of cranial irradiation for brain metastases in people with NSCLC?

- Brain tumours (primary) and brain metastases in adults recommendations discussion

Item 5

Brought forward to day 1, item 8

Item 6

1.3 What is the clinical and cost-effectiveness of routine imaging of the head in the management of people with lung cancer before radical therapy with curative intent?

- Discuss health economics

Item 6

The Chair welcomed SC, Neuroradiologist to the committee. SC introduced himself to the committee. The Chair reviewed SC's, DOI's and these are noted below.

Attendee	Declaration	Action
Steve Connor	Receives payment for work in private hospitals. Paid directly. 95% of private practice fees from HCA insurance. 1/6 of the working week is spent in private practice. Private practice is for general neuroradiology imaging and none in relation to lung cancer.	Direct Financial (non-specific) No action other than the process of open declaration
Steve Connor	Research collaborations with head and neck oncology groups, in regards to head and neck cancer treatment. Not related to the scope of this guideline update.	Non-financial (non-specific) No action other than the process of open declaration No action other than the process of open declaration

RM presented the results of the economic model on routine imaging of the head in

4.0.03 DOC Cmte minutes

the management of people with non-small cell lung cancer before radical therapy with curative intent.
Item 7 1.3 What is the clinical and cost-effectiveness of routine imaging of the head in the management of people with lung cancer before radical therapy with curative intent? <ul style="list-style-type: none">• Discuss health economics• Agree recommendations
Item 7 The committee discussed the results of the health economic model and then reviewed and updated the recommendations accordingly.
Item 8 <ul style="list-style-type: none">• AOB
Item 8 No other business
Item 9 <ul style="list-style-type: none">• Summary and next steps
Item 9 The Chair thanked the committee for their hard work over the 2 day meeting.

Date of next meeting: Thursday 26th July 2018

Location of next meeting: NICE Offices – Manchester